Monday, August 08, 2011 8:07:44 AM
SAN DIEGO, Aug. 8, 2011 /PRNewswire/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today reported financial results for the periods ended June 30, 2011.
"As we head into the second half of the year, we are taking steps to prepare for our launch of Exelbine™ into the U.S. market, should it be approved on or around FDA's PDUFA goal date of September 1, 2011," said Brian M. Culley, Chief Executive Officer of ADVENTRX. "Having a commercial infrastructure will expand our strategic options and increase stockholder value."
Balance Sheet Highlights
As of June 30, 2011, the Company had cash totaling $42.0 million. Stockholders' equity amounted to $46.4 million as of June 30, 2011.
More:
http://finance.yahoo.com/news/ADVENTRX-Reports-Second-prnews-1300038977.html?x=0&.v=1
Looks solid,.
Good luck,. VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM
